Skip to main content
All CollectionsComing Off Antidepressants
Are there risks from staying on antidepressants for many years?
Are there risks from staying on antidepressants for many years?
Updated over a week ago

Studies have identified potential health problems from staying on antidepressants long-term, such as:

  • Increased risk of developing osteoporosis*

  • Increased risk of bleeding*

  • Negative effects on the liver**

  • Increased risk of cataracts**

  • Increased risk of cardiovascular disease***

  • Increased risk of an early death*

  • Some antidepressants have been associated with an increased risk of dementia****

  • Using an antidepressant for longer also increases the likelihood of withdrawal symptoms when the dose is reduced or stopped*****

Tolerance or “poop-out” also may occur from long-term antidepressant use. This brings on a gradual need to increase the dose of their medication over time, with less and less effect.******

Some studies suggest long-term use of antidepressants can cause low mood, possibly due to extended drug effects on the brain.*******


* Coupland, Carol, Paula Dhiman, Richard Morriss, Antony Arthur, Garry Barton, and Julia Hippisley-Cox. 2011. “Antidepressant Use and Risk of Adverse Outcomes in Older People: Population Based Cohort Study.” BMJ 343 (aug02 1): d4551.https://www.bmj.com/content/343/bmj.d4551

** Carvalho, André F., Manu S. Sharma, André R. Brunoni, Eduard Vieta, and Giovanni A. Fava. 2016. “The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature.” Psychotherapy and Psychosomatics 85 (5): 270–88. https://www.karger.com/Article/FullText/447034

*** Bansal, Narinder, Mohammed Hudda, Rupert A. Payne, Daniel J. Smith, David Kessler, and Nicola Wiles. 2022. “Antidepressant Use and Risk of Adverse Outcomes: Population-Based Cohort Study.” BJPsych Open 8 (5): e164. https://www.cambridge.org/core/journals/bjpsych-open/article/antidepressant-use-and-risk-of-adverse-outcomes-populationbased-cohort-study/6AAA6943E55F8B08DD9E25155E72931F

**** Richardson, Kathryn, Chris Fox, Ian Maidment, Nicholas Steel, Yoon K. Loke, Antony Arthur, Phyo K. Myint, et al. 2018. “Anticholinergic Drugs and Risk of Dementia: Case-Control Study.” BMJ 361 (April): k1315. https://www.bmj.com/content/361/bmj.k1315

***** Horowitz, M. A., Adele Framer, Michael P. Hengartner, Anders Sorensen, and David M. Taylor. 2022. “Estimating Risk of Withdrawal from a Review of Published Data (Accepted manuscript - CNS Drugs).”

****** Kinrys, Gustavo, Alexandra K. Gold, Vincent D. Pisano, Marlene P. Freeman, George I. Papakostas, David Mischoulon, Andrew A. Nierenberg, and Maurizio Fava. 2019. “Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research.” Journal of Affective Disorders 245 (October 2018): 488–97. https://www.sciencedirect.com/science/article/abs/pii/S0165032718316859?via%3Dihub

******* El-Mallakh, Rif S., Yonglin Gao, Brian T. Briscoe, and R. Jeannie Roberts. 2011. “Antidepressant-Induced Tardive Dysphoria.” Psychotherapy and Psychosomatics 80 (1): 57–59. https://www.karger.com/Article/Abstract/316799

Did this answer your question?